medigraphic.com
ISSN 1527-3172 (Electronic)

2014, Number 3-4

<< Back Next >>

MEDICC Review 2014; 16 (3-4)

Immunotherapy and complexity: Overcoming barriers to control of advanced cancer

Lage DA

Language: English
References: 65
Page: 65-72
PDF size: 148.27 Kb.


ABSTRACT

Recent advances in fundamental immunology are changing paradigms for management of advanced cancer, now acknowledged as a chronic disease whose prevalence will increase, and one whose complexity makes it difficult to control. Immunotherapy is emerging as an alternative, with new monoclonal antibodies, therapeutic vaccines and deeper understanding of fundamental phenomena in the interaction between tumor and immune system. These novel insights concern mechanisms of programmed contraction of the immune response, characterization of molecular and cellular markers of immunosenescence, the dual role of inflammation, characterization of myeloid-derived suppressor cells and cancer stem cells, and the phenomena of immunogenic apoptosis and oncogene addiction.
Additionally, new data drive a deeper understanding of four barriers to overcome in control of advanced cancer: the complexity of biological systems, tumor heterogeneity, tumor mutation rates, and human genome–environment mismatch. The new landscape points to six main strategies: manage advanced cancer as a chronic disease, find relevant molecular markers for patient stratification, develop a rationale for therapeutic combinations, target regulatory control loops in the immune system, expand mathematical modeling capacity, and evaluate complex health intervention packages in real-world conditions.


REFERENCES

  1. World Health Organization. Cancer Control: Knowledge Into Action: WHO Guide for Effective Programmes: Module 4. Geneva: World Health Organization; 2008.

  2. Programa integral para el control del cáncer en Cuba. Estrategia Nacional para el Control del Cáncer. Havana: Editorial Ciencias Médicas; 2012. Spanish.

  3. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, et al. Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2013 Jan 1;31(1):131–61.

  4. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012 Apr;23(4):1044–52.

  5. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013 Jun;13(6):745–58.

  6. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012 Jul–Aug;62(4):220–41.

  7. Lage A, Crombet T. Control of advanced cancer: the road to chronicity. Int J Environ Res Public Health. 2011 Mar;8(3):683–97.

  8. Berlinger N, Gusmano M. Cancer chronicity: new research and policy challenges. J Health Serv Res Policy. 2011 Apr;16(2):121–3.

  9. Sankaranarayanan R, Boffetta P. Research on cancer prevention, detection and management in low- and medium-income countries. Ann Oncol. 2010 Oct;21(10):1935–43.

  10. Hsieh MH, Meng MV. Prostate Cancer Screening and Risk of Litigation: Caught Between Scylla and Charybdis. J Urol. 2014 Mar 18. doi: 10.1016/ j.juro.2014.03.085. [Epub ahead of print].

  11. Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014 Jan;35(1):41–50.

  12. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278–87.

  13. Biologics. Medicines in Development. 2013 Report [Internet]. Washington, DC: Pharmaceutical Research and Manufacturers of America (PhRMA); c2013 [cited 2014 Mar 21]. 87 p. Available from: http://www.phrma.org/sites/default/

  14. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–23.

  15. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013 Dec 20;342(6165):1432–3.

  16. Díaz A, Martínez GS. Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. Onco Targets Ther. 2013 Jul 24;6:931–42.

  17. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8(+) T cells after infection. Nat Immunol. 2002 Jul;3(7):619–26.

  18. Wherry EJ. T cell exhaustion. Nat Immunol. 2011 Jun;12(6):492–9.

  19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–64.

  20. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012 Apr;24(2):207–12.

  21. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793–800.

  22. Dolan DE, Gupta S. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control. 2014 Jul;21(3):231–7.

  23. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–79.

  24. León K, García K, Carmenate T. Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics. Front Immunol. 2013 Dec 11;4:439.

  25. García K, León K. Modeling the role of IL-2 in the interplay between CD4+ helper and regulatory T cells: assessing general dynamical properties. J Theor Biol. 2010 Feb 21;262(4):720–32.

  26. Carmenate T, Pacios A, Enamorado M, Moreno E, García K, Fuente D, et al. Human IL-2 mutein J Immunol. 2013 Jun 15;190(12):6230–8.

  27. Fulop T, Larbi A, Kotb R, Pawelec G. Immunology of aging and cancer development. Interdiscip Top Gerontol. 2013;38:38–48.

  28. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013 May;14(5):428–36.

  29. Garcia B, Saavedra D, Lorenzo P, Badía T, Leonard I, Lage A, et al. Immunosenescence and gender: a study in healthy Cubans. Immun Ageing. 2013 Apr 30;10(1):16.

  30. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.

  31. Colotta F, Allavena P, Sica A, Garlanda C, seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009 Jul;30(7):1073–81.

  32. immune surveillance in cancer. Semin Cancer Biol. 2012 Feb;22(1):23–32.

  33. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA. 2007 Apr 10;104(15):6223–8.

  34. Wesolowski R, Markowitz J, Carson WE 3rd. Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013 Jul 15;1:10.

  35. Montero AJ, Díaz CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012 Feb–Mar;35(2):107–15.

  36. Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, et al. Inhibition of tumorinduced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol. 2011 Jan 1;186(1):264–74.

  37. Oliver L, Fernández A, Raymond J, López A, Fernández LE, Mesa C. Very small size proteoliposomes derived from Neisseria meningitidis: - toxic T lymphocyte response stimulation under leukopenic conditions. Vaccine. 2012 Apr 19;30(19):2963–72.

  38. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011 Mar;17(3):313–9.

  39. Díaz A, Rolff J, Lemm M, Fichtner I, Pérez R, Montero E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer. 2009 Mar 24;100(6):950–8.

  40. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.

  41. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012 Feb 3;11(3):215–33.

  42. Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth J Immunol. 2011 Nov 15;187(10):4954–66.

  43. Osorio M, García E, Rodríguez E, Saurez G, Arango C, Noris E, et al. Heterophilic NeuGc- GM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther. 2008 Apr;7(4):488–95.

  44. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080. doi: 10.1158/0008-5472.CAN-07-3293. Review.

  45. Pérez R, Crombet T, de León J, Moreno E. A view on EGFR-targeted therapies from the oncogeneaddiction perspective. Front Pharmacol. 2013 Apr 26;4:53.

  46. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7;444(7120):756–60.

  47. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006 Dec;18(12):2089–97.

  48. Complicated is not complex [Editorial]. Nat Biotechnol. 1999 Jun;17(6):511. doi: 10.1038/9772.

  49. Lage A. Immunotherapy and Immunoregulation: The Barrier of Complexity. Biotecnol Aplicada. 2002 Jul–Dec;19(3–4):175–7.

  50. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013 Sep 19;501(7467):338–45.

  51. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519–25.

  52. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Díaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546–58.

  53. Kirkwood TB. Time of our lives. What controls the length of life? EMBO Rep. 2005 Jul;6 Spec No:S4–8.

  54. driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008 Dec;2(6):218–30.

  55. Garrote LF, Alvarez YG, Babie PT, Yi MG, Alvarez MG, Cicili ML. Cancer survival in Cuba, 1994–1995. IARC Sci Publ. 2011;(162):89–95.

  56. Pikor LA, Ramnarine VR, Lam S, Lam WL. and their therapeutic implications. Lung Cancer. 2013 Nov;82(2):179–89.

  57. Pascual MR, Macías A, Moreno L, Lage A. Factors associated with prognosis in human breast cancer. V. The simultaneous use of estrogen and progesterone receptor measurements for prediction of short-term relapse. Neoplasma. 1985;32(2):247–56.

  58. Gómez C, Plaza JC, Pazo R, Salud A, Pons F,- cation predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol. 2013 Dec 10;31(35):4445–52.

  59. Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer. 2013 May;80(2):120–30.

  60. Murray S, Karavasilis V, Bobos M, Razis E, Papadopoulos S, Christodoulou C, et al. Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. J Exp Clin Cancer Res. 2012 Sep 19;31:77.

  61. Rodríguez MO, Rivero TC, del Castillo R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010 Mar 1;9(5):343–9.

  62. Crombet T, Neninger E, González J, Rodríguez PC, García B, Popa X, et al. EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers. J Clin Oncol. 2013;31 (Suppl; abstr 3013).

  63. León K, Lage A, Carneiro J. Tolerance and immunity in a mathematical model of T-cell mediated suppression. J Theor Biol. 2003 Nov 7;225(1):107–26.

  64. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009 Jun 1;69(11):4894–903.

  65. Brainy Quotes [Internet]. [place unknown]: Xplore, Inc; c2001–2014 [cited 2014 Jun 7]; [about 1 screen]. Available from: http:// www.brainyquote.com/quotes/quotes/a/alber teins112012.html




2020     |     www.medigraphic.com